NaviFUS Corp. Advances Non-Invasive Precision Medicine for Brain Disorders with Taiwan's Chip Technology

Whats Happening:

NaviFUS Corp. is developing innovative ultrasound-based solutions for brain disorder treatments, leveraging Taiwan's advanced chip technology. Their system uses transcranial focused ultrasound for drug delivery and neuromodulation, offering new hope for patients with brain cancer and drug-resistant epilepsy. The company has completed successful clinical trials and is expanding globally through strategic partnerships.

Key Moves:

• NaviFUS completed a Phase II trial for recurrent glioblastoma with promising results

• The company is conducting ongoing trials for drug-resistant epilepsy in multiple countries

• NaviFUS is collaborating with Brainlab to enhance treatment precision and global reach

By The Numbers:

• 66.7% progression-free survival at six months for rGBM patients (vs. historical 42.6%)

• Median progression-free survival of 8.9 months for rGBM patients (vs. historical 4.2 months)

• Brainlab's network includes 6,300 hospitals in 120 countries

Key Quotes:

• Chairman Jen Chen emphasized Taiwan's commitment to biomedical advancements

• Acer founder Stan Shih highlighted NaviFUS' role during the company's pre-listing presentation

Bottom Line:

NaviFUS Corp. is at the forefront of non-invasive brain treatments, combining Taiwan's chip technology with focused ultrasound. Their promising clinical results and strategic partnerships position them as a leader in precision medicine for brain disorders, potentially transforming treatment options for patients worldwide.

Read Full Article